^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:Prostate Cancer
    Drug:Nubeqa (darolutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    PTEN loss as a potential biomarker in patients with castration resistant prostate cancer M0.

    Published date:
    05/19/2021
    Excerpt:
    In the PTEN loss population 2 patients received apalutamide plus ADT and 2 darolutamide plus ADT, these patients were excluded for the MFS analysis...Median MFS was 37 months in the PTEN loss population vs. 23 months in the PTEN non-loss…